Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Early Assessment of Pulmonary Inflammation by 19F MRI In VivoCLINICAL PERSPECTIVE by Bernd Ebner, Patrick Behm, Christoph Jacoby, Sandra Burghoff, Brent A. French, Jürgen Schrader, and Ulrich Flögel Circ Cardiovasc Imaging Volume 3(2):202-210 March 16, 2010 Copyright © American Heart Association, Inc. All rights reserved. Figure 1. 19F signals precede structural changes in LPS-induced pneumonia. Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 2. Observed 19F signals are dose dependent. Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 3. Detected PFC patterns correspond to histological distribution of inflammatory cells. Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 4. PFC distribution in blood cells under control conditions and LPS challenge. 1H and 19F MRIs of 15-mL Falcon tubes after density gradient centrifugation of mouse blood collected 2, 12, 24, 48, and 72 hours after PFC injection showing the accumulation of 19F signals in MNPs and PMNs. A, Time course of PFC label in vehicle-treated animals (1.5 μL saline/g BW) and B, LPStreated animals (0.3 μg/g BW in 1.5 μL saline/g BW). Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 5. FACS analysis of inflamed lungs: MNPs and PMNs transport 19F. Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 6. Monitoring therapy by 19F MRI. Anti-inflammatory treatment was performed with dexamethasone (DEX, 1 μg/g BW), the adenosine 2A receptor agonist CGS21680 (CGS, 2 μg/g BW), and vehicle (DMSO, 1 μL/g BW) after pulmonary challenge with LPS (0.3 μg/g BW). Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved. Figure 7. Correlation of 19F signals and biological markers of lung inflammation after drug treatment. Bernd Ebner et al. Circ Cardiovasc Imaging. 2010;3:202-210 Copyright © American Heart Association, Inc. All rights reserved.